Literature DB >> 7573590

Early nonresponse to fluoxetine as a predictor of poor 8-week outcome.

A A Nierenberg1, N E McLean, J E Alpert, J J Worthington, J F Rosenbaum, M Fava.   

Abstract

OBJECTIVE: The purpose of this study was to quantify the proportion of patients who show no response to a fixed dose of fluoxetine after 2, 4, and 6 weeks of treatment and then respond by week 8.
METHOD: In an open trial, 143 outpatients who met DSM-III-R criteria for major depressive disorder were treated with a regimen of fluoxetine, 20 mg/day. The authors analyzed the proportion of patients who had less than a 20% decrease from baseline in their scores on the Hamilton Rating Scale for Depression after 2, 4, and 6 weeks and who went on to have a 50% or greater reduction by week 8. A last-observation-carried-forward strategy was used to calculate conditional probabilities of 8-week response. Kaplan-Meier survival analysis was used to estimate probabilities of response at week 8 given degrees of response at week 2.
RESULTS: Eighty-two subjects (57.3%) who started the trial responded by week 8. Of those subjects who showed no improvement at weeks 2, 4, and 6, the proportions of responders at week 8 were 36.4%, 18.9%, and 6.5%, respectively. The Kaplan-Meier estimate of 8-week response given nonresponse at week 2 was 0.45.
CONCLUSIONS: The proportion of patients with no response to antidepressant treatment by 4 or 6 weeks who responded by week 8 was substantially less than that for subjects who had at least a partial response. Nonresponse as early as week 2 predicted 8-week outcome.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7573590     DOI: 10.1176/ajp.152.10.1500

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  31 in total

1.  Assessment of subclinical symptoms and psychological well-being in depression.

Authors:  G A Fava; L Mangelli
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2001       Impact factor: 5.270

2.  Do early changes in the HAM-D-17 anxiety/somatization factor items affect the treatment outcome among depressed outpatients? Comparison of two controlled trials of St John's wort (Hypericum perforatum) versus a SSRI.

Authors:  Stella Bitran; Amy H Farabaugh; Victoria E Ameral; Rachel A LaRocca; Alisabet J Clain; Maurizio Fava; David Mischoulon
Journal:  Int Clin Psychopharmacol       Date:  2011-07       Impact factor: 1.659

3.  Clinical value of early partial symptomatic improvement in the prediction of response and remission during short-term treatment trials in 3369 subjects with bipolar I or II depression.

Authors:  David E Kemp; Stephen J Ganocy; Martin Brecher; Berit X Carlson; Suzanne Edwards; James M Eudicone; Gary Evoniuk; Wim Jansen; Andrew C Leon; Margaret Minkwitz; Andrei Pikalov; Hans H Stassen; Armin Szegedi; Mauricio Tohen; Arjen P P Van Willigenburg; Joseph R Calabrese
Journal:  J Affect Disord       Date:  2010-11-10       Impact factor: 4.839

4.  Sub-hubs of baseline functional brain networks are related to early improvement following two-week pharmacological therapy for major depressive disorder.

Authors:  Yuedi Shen; Jiashu Yao; Xueyan Jiang; Lei Zhang; Luoyi Xu; Rui Feng; Liqiang Cai; Jing Liu; Jinhui Wang; Wei Chen
Journal:  Hum Brain Mapp       Date:  2015-04-30       Impact factor: 5.038

5.  Report of two double-blind randomized placebo-controlled pilot studies of a carbohydrate-rich nutrient mixture for treatment of seasonal affective disorder (SAD).

Authors:  David Mischoulon; Paola Pedrelli; Judith Wurtman; Mark Vangel; Richard Wurtman
Journal:  CNS Neurosci Ther       Date:  2009-09-21       Impact factor: 5.243

6.  Initial rate of improvement in relation to remission of major depressive disorder in primary care.

Authors:  Anton C Vergouwen; Huibert Burger; Frank Koerselman; Theo J Verheij
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

Review 7.  Pharmacotherapy to sustain the fully remitted state.

Authors:  Sidney Kennedy; Roger McIntyre; Angelo Fallu; Raymond Lam
Journal:  J Psychiatry Neurosci       Date:  2002-07       Impact factor: 6.186

Review 8.  Psychosocial and clinical predictors of response to pharmacotherapy for depression.

Authors:  R Michael Bagby; Andrew G Ryder; Carolina Cristi
Journal:  J Psychiatry Neurosci       Date:  2002-07       Impact factor: 6.186

9.  Early improvement with lithium in classic mania and its association with later response.

Authors:  Rodrigo Machado-Vieira; David A Luckenbaugh; Marcio G Soeiro-de-Souza; Getulio Marca; Ioline D Henter; Joao V Busnello; Wagner F Gattaz; Carlos A Zarate
Journal:  J Affect Disord       Date:  2012-08-17       Impact factor: 4.839

10.  Bayesian modelling and ROC analysis to predict placebo responders using clinical score measured in the initial weeks of treatment in depression trials.

Authors:  Roberto Gomeni; Emilio Merlo-Pich
Journal:  Br J Clin Pharmacol       Date:  2007-05       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.